Tiny study probes why some melanoma patients respond to immunotherapy
NCT ID NCT03225365
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study involved 5 people with advanced melanoma who were treated with immunotherapy drugs (nivolumab with or without ipilimumab). Researchers wanted to understand how the immune system changes during treatment and what makes some patients respond better than others. They took blood and skin samples to analyze immune cells, but the study was small and focused on gathering information, not testing a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Dermatologie, Centre Hospitalier Lyon Sud (HCL)
Pierre-Bénite, 69310, France
Conditions
Explore the condition pages connected to this study.